Abstract
Background Previous studies on pacemaker-associated heart failure (PaHF) have predominantly analyzed relatively small, single-center datasets, mainly focusing on incidence and predictors. However, the clinical implications of PaHF on mortality, particularly in relation to standard HF medications or upgrading to cardiac resynchronization therapy (CRT), has been underexplored.
Methods Utilizing nationwide real-world data from the Korean National Health Insurance Service database, we analyzed 32,216 patients undergoing permanent pacemaker (PPM) implantation without preexisting HF between 2008 and 2019. The incidence, predictors, and mortality risk of PaFH were evaluated. To address potential immortal-time bias due to the time-dependent occurrence of PaHF, the time from the PPM implantation to the first diagnosis of PaHF was analyzed as a time-dependent covariate. For patients with PaHF, a propensity score-matched analysis was conducted based on CRT-upgrade status to explore the effect of CRT-upgrade on the risk of all-cause mortality.
Results During the median 3.8-year follow-up period, PaHF and all-cause death occurred in 4170 (12.9%) and 6184 (19.2%) of the 32,216 PPM patients (42.3% male, mean age 70.6 years), respectively. PaHF development was closely associated with all-cause mortality, with a significantly higher mortality risk in the PaHF than in the non-PaHF group (hazard ratio [HR]=3.11, 95% confidence interval [CI]=2.93–3.32, P<0.001) after adjusting for immortal-time bias. The PaHF incidence and PaHF-associated mortality risk, although highest for the first six months post-PPM, did not disappear and increased again with follow-up time. In both the entire cohort (n=4170) and the propensity score-matched cohort (n=1685) of PaHF patients, CRT upgrade (HR=0.34, 95% CI=0.24–0.47, P<0.001), the use of beta-blockers (HR=0.75, 95% CI=0.61–0.93, P=0.010), and angiotensin receptor neprilysin inhibitor (ARNI) use (HR=0.28, 95% CI=0.14–0.54, P<0.001) were identified as potent protective factors against post-PaHF all-cause mortality.
Conclusions PaHF development independently predicted post-PPM mortality, while upgrading to CRT and the use of beta-blockers or ARNI were identified as favorable prognostic factors for post-PaHF overall survival. Therefore, for PaHF patients, an immediate change into CRT or conduction system pacing, may be required along with optimal HF medications owing to the ongoing mortality risk.
Competing Interest Statement
S.J.-P. received research grants from Boston Scientific, Biotronik, Abbott, and Medtronic. K.-P. received research grants from Boston Scientific. Y.K.-O. received research grants from Bayer AG, Daiichi Sankyo Company. All other authors declare no conflicts of interest
Clinical Trial
This study is a retrospective study using an anonymized database in the country.
Funding Statement
None declared.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Institutional Review Board (IRB) of Samsung Medical Center (IRB File No. 2019-05-075). The requirement of informed consent was waived as data are public and deidentified under confidentiality guidelines.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data sharing from the Authors is not possible because of legislation from the Korean government. However, additional data are available through approval and oversight by the Korean National Health Insurance Service
Abbreviations
- ACEI
- angiotensin-converting-enzyme inhibitors
- AF
- atrial fibrillation
- ARB
- angiotensin II receptor blockers
- ARNI
- angiotensin receptor neprilysin inhibitor
- AVB
- atrioventricular block
- CCI
- Charlson comorbidity index
- CKD
- chronic kidney disease
- CRT
- cardiac resynchronization therapy
- DM
- diabetes mellitus
- EF
- ejection fraction
- ESRD
- end-stage renal disease
- MRA
- mineralocorticoid receptor antagonists
- PaHF
- pacemaker-associated
- HF PPM
- Permanent pacemaker
- SND
- sinus node dysfunction
